Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Triptorelin Pamoate

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Triptorelin is a decapeptide as a GnRH (gonadotropin-releasing hormone) agonist under the development of Pfizer. It decreases pituitary secretion of gonadotropins luteinizing hormoneand follicle stimulating hormone by causing constant stimulation of the pituitary. Triptorelin can be used in the treatment of hormone-responsive cancers including prostate cancer and breast cancer, precocious puberty, estrogen-dependent conditions including endometriosis and uterine fibroids, in assisted reproduction and gender identity disorder.

Category

Peptide Inhibitors

Catalog number

BAT-010065

CAS number

124508-66-3

Molecular Formula

C87H98N18O19

Molecular Weight

1699.85

Size	Price	Stock	Quantity
5 mg	$293	In stock

Specification
Reference Reading

IUPAC Name

(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid

Synonyms

NCGC00164636-01; DSSTox_CID_26494; DSSTox_RID_81664; DSSTox_GSID_46494; DTXSID4046494;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2R)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide;4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;57773-63-4 (net);AY 25650; CL118532;Wy4 2462; D-Trp-6-LH-RH

Related CAS

57773-63-4 (free base) 140194-24-7 (Acetate)

Appearance

Powder

Purity

98%

Sequence

XHWSYWLRPG

Storage

Store at -20°C

Solubility

Soluble in DMSO

Application

hormone-responsive cancers;precocious puberty;estrogen-dependent conditions;in assisted reproduction ;gender identity disorder

InChI

InChI=1S/C64H82N18O13.C23H16O6/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-

InChI Key

ZBVJFYPGLGEMIN-IKNXIQPFSA-N

Canonical SMILES

CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O

1.Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.

Siristatidis CS1, Gibreel A, Basios G, Maheshwari A, Bhattacharya S. Cochrane Database Syst Rev. 2015 Nov 9;11:CD006919. doi: 10.1002/14651858.CD006919.pub4.

BACKGROUND: Gonadotrophin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising the chances of live birth.

2.Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.

Lebret T1, Rouanne M1, Hublarov O2, Jinga V3, Petkova L4, Kotsev R5, Sinescu I6, Dutailly P7. Ther Adv Urol. 2015 Jun;7(3):125-34. doi: 10.1177/1756287215577329.

OBJECTIVES: Gonadotropin-releasing hormone agonists are widely used as androgen deprivation therapy in many men with locally advanced or metastatic prostate cancer. Gonadotropin-releasing hormone agonists are delivered by intramuscular injection every 1, 3 or 6 months, but in some patients subcutaneous injection may be more appropriate. This study assessed the efficacy and safety profile of the gonadotropin-releasing hormone agonist, triptorelin pamoate, when administered by the subcutaneous route.

3.Long-term contraception in a small implant: A review of Suprelorin (deslorelin) studies in cats.

Fontaine C1. J Feline Med Surg. 2015 Sep;17(9):766-71. doi: 10.1177/1098612X15594990.

RATIONALE: Deslorelin (Suprelorin®; Virbac) is a gonadotropin-releasing hormone (GnRH) agonist licensed in select countries for the long-term suppression of fertility in adult male dogs and male ferrets. This article summarizes studies investigating the use of deslorelin implants for the long-term suppression of fertility in male and female domestic cats.

4.MEDICAL MANAGEMENT OF LEIOMYOMATA AND SUSPECTED ENDOMETRIOSIS IN AN ALLEN'S SWAMP MONKEY (ALLENOPITHECUS NIGROVIRIDUS).

Jafarey YS, Hanley CS, Berlinski RA, Warner C, Armstrong A. J Zoo Wildl Med. 2015 Dec;46(4):913-7. doi: 10.1638/2014-0224.1.

A 13-yr-old female nulliparous Allen's swamp monkey (Allenopitchecus nigroviridis) presented with intermittent excessive vaginal bleeding, cyclical lethargy, and a history of irregular menstrual cycles. Abdominal ultrasonography revealed a subjectively thickened, irregular endometrium, multiple leiomyomata (uterine fibroids), and bilateral anechoic foci on the ovaries. Treatment was initiated with leuprolide acetate i.m. monthly for 6 mo. Recheck ultrasound at 3 mo showed a decrease in leiomyoma diameter and no evidence of active follicles on the ovaries. Eleven months following completion of treatment, clinical signs recurred and the animal was treated with a deslorelin implant. Since implant placement, no vaginal bleeding has been noted.